MCID: PRP036
MIFTS: 48

Peripheral T-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 37 72 49 69
Peripheral T Cell Lymphoma 36
Lymphoma T-Cell Peripheral 51

Classifications:



External Ids:

KEGG 36 H01892
ICD10 32 C84.4
UMLS 69 C0079774

Summaries for Peripheral T-Cell Lymphoma

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to lymphoma and anaplastic large cell lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are Transcriptional misregulation in cancer and B Cell Development Pathways. The drugs Beleodaq and Folotyn have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotype is neoplasm.

Wikipedia : 72 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 lymphoma 30.7 ALK BCL6 TCL1A TIA1
2 anaplastic large cell lymphoma 30.4 ALK GZMB
3 alk-negative anaplastic large cell lymphoma 30.2 ALK CXCR3
4 panniculitis 30.2 GZMB TIA1
5 subcutaneous panniculitis-like t-cell lymphoma 30.2 GZMB TIA1
6 composite lymphoma 30.2 BCL6 GZMB TIA1
7 lymphomatoid papulosis 29.8 ALK GZMB TIA1
8 b-cell lymphomas 29.8 BCL6 MS4A1 TCL1A
9 mycosis fungoides 29.7 CXCR3 GZMB TIA1
10 lymphoma, mucosa-associated lymphoid type 29.4 BCL6 CXCR3
11 t-cell prolymphocytic leukemia 29.2 MS4A1 TCL1A
12 lymphoma, hodgkin, classic 29.1 ALK BCL6 GZMB MS4A1 TIA1
13 leukemia, chronic lymphocytic 28.8 BCL6 CXCR3 MS4A1 TCL1A
14 primary cutaneous peripheral t-cell lymphoma not otherwise specified 12.6
15 enteropathy-associated t-cell lymphoma 11.6
16 primary cutaneous aggressive epidermotropic cd8+ t-cell lymphoma 10.8
17 primary cutaneous gamma/delta-positive t-cell lymphoma 10.4
18 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.4
19 orbit lymphoma 10.4 GZMB TIA1
20 lichen sclerosus et atrophicus 10.4 GZMB TIA1
21 leukemia 10.4
22 angioimmunoblastic t-cell lymphoma 10.4
23 lymphomatoid granulomatosis 10.4 GZMB TIA1
24 viral esophagitis 10.4 GZMB TIA1
25 diffuse large b-cell lymphoma 10.4
26 lymphocytic gastritis 10.4 GZMB TIA1
27 natural killer cell leukemia 10.3 GZMB TIA1
28 hepatosplenic t-cell lymphoma 10.3 GZMB TIA1
29 choriocarcinoma of the testis 10.3 GZMB TIA1
30 chops syndrome 10.3
31 giardiasis 10.3 GZMB TIA1
32 infiltrating lipoma 10.3 GZMB TIA1
33 necrotizing sialometaplasia 10.3 GZMB TIA1
34 erythema multiforme 10.2 CXCR3 GZMB
35 blood group, i system 10.1
36 adult t-cell leukemia 10.1
37 t-cell leukemia 10.1
38 hypereosinophilic syndrome 10.1
39 leukemia, chronic lymphocytic 2 10.1
40 hepatitis 10.1
41 leukemia, b-cell, chronic 10.1
42 cutaneous lupus erythematosus 10.1 CXCR3 GZMB
43 primary cutaneous anaplastic large cell lymphoma 10.1 ALK GZMB TIA1
44 breast lymphoma 10.1 ALK BCL6
45 bronchiolitis obliterans 10.1 CXCR3 GZMB
46 colon lymphoma 10.1 ALK BCL6
47 myelofibrosis 10.1
48 autoimmune lymphoproliferative syndrome, type v 10.1
49 hematopoietic stem cell transplantation 10.1
50 hemophagocytic lymphohistiocytosis 10.1

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 ALK CXCR3 ETV6 NME1

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Beleodaq 17 45 BELINOSTAT Spectrum Pharmaceuticals July 2014
2
Folotyn 17 45 PRALATREXATE Allos Therapeutics September 2009
3
Istodax 17 45 ROMIDEPSIN Gloucester Pharmaceuticals November 2009

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
10
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
13
Asparaginase Approved, Investigational Phase 4,Early Phase 1 9015-68-3
14
Mechlorethamine Approved, Investigational Phase 4,Phase 2,Phase 1 51-75-2 4033
15
Epirubicin Approved Phase 4,Phase 1,Phase 2 56420-45-2 41867
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
18
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
19
Pirarubicin Investigational Phase 4 72496-41-4
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
22 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1,Early Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
28 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
34 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Methylprednisolone acetate Phase 4,Phase 1,Phase 2
40 Methylprednisolone Hemisuccinate Phase 4,Phase 1,Phase 2
41 Prednisolone acetate Phase 4,Phase 1,Phase 2
42 Prednisolone hemisuccinate Phase 4,Phase 1,Phase 2
43 Prednisolone phosphate Phase 4,Phase 1,Phase 2
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antiemetics Phase 4,Phase 2,Phase 1,Early Phase 1
46 Autonomic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 BB 1101 Phase 4,Phase 2,Phase 1,Early Phase 1
48 Dexamethasone acetate Phase 4,Phase 2,Phase 1,Early Phase 1 1177-87-3
49 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Early Phase 1
50 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 227)

# Name Status NCT ID Phase Drugs
1 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
2 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
3 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
4 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
5 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
7 Alemtuzumab and CHOP in T-cell Lymphoma Unknown status NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
8 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
9 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
10 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Active, not recruiting NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
11 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Active, not recruiting NCT03349333 Phase 3 pralatrexate
12 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
13 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Not yet recruiting NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
14 Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Not yet recruiting NCT03355768 Phase 3 Romidepsin;Pralatrexate
15 Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients Terminated NCT01420679 Phase 3 Pralatrexate Injection
16 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
17 Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Unknown status NCT02520219 Phase 2 GDP
18 Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma Unknown status NCT00136565 Phase 2 Velcade + ACVBP regimen
19 Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
20 Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Unknown status NCT00632827 Phase 2 REGIMEN;REGIMEN B
21 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Unknown status NCT00211185 Phase 2 ONTAK (denileukin diftitox, DAB389 IL-2)
22 Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) Unknown status NCT00840385 Phase 2 FAD
23 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
24 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma Unknown status NCT01307592 Phase 2 gemcitabine hydrochloride;lenalidomide;oxaliplatin
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 Allo-hNHL (FluBuCy) Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
28 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
29 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Completed NCT01806337 Phase 2 Alemtuzumab
30 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
31 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Completed NCT00888927 Phase 1, Phase 2
32 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) Completed NCT00930605 Phase 2 CHOP regimen alternate with ESHAP regimen;Alemtuzumab
33 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
34 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
35 Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Completed NCT01611142 Phase 2
36 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
37 A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas Completed NCT01280526 Phase 1, Phase 2 Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP
38 Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas Completed NCT00453427 Phase 1, Phase 2 Alemtuzumab (Campath-1H)
39 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
40 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Completed NCT00337987 Phase 2 Ontak;CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
41 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
42 A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Completed NCT00791947 Phase 2 CHOEP + G-CSF followed by BEAM
43 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Completed NCT02158975 Phase 2 MLN9708
44 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy
45 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients Completed NCT01776411 Phase 1, Phase 2 forodesine hydrochloride
46 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Completed NCT00290433 Phase 2 Cyclophosphamide;Mesna;Vincristine;Methotrexate;Ara-C;Dexamethasone;G-CSF;Doxil
47 Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms Completed NCT00217425 Phase 2 cyclophosphamide;doxorubicin;prednisone;vincristine
48 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade
49 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed NCT01226472 Phase 2
50 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

38
T Cells, B Cells, Bone, Thymus, Bone Marrow, Liver, Colon

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 728)
# Title Authors Year
1
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). ( 29397528 )
2018
2
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
3
Peripheral T-cell lymphoma mimicking classic Hodgkin's lymphoma in a patient presenting with fevers of unknown origin. ( 29420242 )
2018
4
Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. ( 29305415 )
2018
5
Central Nervous System Involvement in Peripheral T Cell Lymphoma. ( 29374824 )
2018
6
Peripheral T-cell lymphoma: novel backbone. ( 29371206 )
2018
7
Pathogenesis of Peripheral T Cell Lymphoma. ( 29414251 )
2018
8
Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. ( 29269644 )
2018
9
Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database. ( 29214867 )
2017
10
Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab. ( 28937435 )
2017
11
Composite lymphoma of peripheral T-cell lymphoma and Hodgkin lymphoma, mixed cellularity type; pathological and molecular analysis. ( 28191697 )
2017
12
Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma. ( 28699695 )
2017
13
Early diagnosis of an isolated primary peripheral T-cell lymphoma masquerading as massive gingival enlargement in a pediatric patient. ( 29391718 )
2017
14
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. ( 29242582 )
2017
15
Follicular variant of peripheral T-cell lymphoma. ( 28631651 )
2017
16
Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. ( 28864629 )
2017
17
Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. ( 29253087 )
2017
18
Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment. ( 28924126 )
2017
19
Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. ( 29190917 )
2017
20
Peripheral T-Cell Lymphoma in Mediastinum Lymph Nodes and Lung Associated to Histoplasmosis in a Patient with Chronic Lymphoid Leukemia/Small Lymphocytic Lymphoma. ( 28698787 )
2017
21
Rapid Evolving Unilateral Indurated Oozing Facial Plaques in a Patient with Head-and-Neck Cancer: Peripheral T-Cell Lymphoma Not Otherwise Specified (NOS). ( 28785337 )
2017
22
A case of peripheral T-cell lymphoma, not otherwise specified, with rapid progression to erythroderma. ( 29171401 )
2017
23
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? ( 27696517 )
2017
24
Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. ( 29296861 )
2017
25
Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3). ( 28659334 )
2017
26
Peripheral T-Cell Lymphoma of the Submandibular Salivary Gland as an Unusual Manifestation of Richter's Syndrome: A Case Report and Literature Review. ( 29410924 )
2017
27
Case of peripheral T-cell lymphoma, not otherwise specified, presenting dyshidrosis-like eruptions as the first clinical manifestation. ( 28868736 )
2017
28
Peripheral T-cell lymphoma, not otherwise specified. ( 29302559 )
2017
29
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
30
Primary hepatic peripheral T-cell lymphoma mimicking hepatocellular carcinoma: a case report. ( 28835888 )
2017
31
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy. ( 29245981 )
2017
32
Mediastinal peripheral T-cell lymphoma diagnosed by repeated biopsies after an initial diagnosis of fibrosing mediastinitis. ( 28932400 )
2017
33
Expansion of NKG2C-expressing Natural Killer Cells after Umbilical Cord Blood Transplantation in a Patient with Peripheral T-Cell Lymphoma with Cytotoxic Molecules. ( 29269653 )
2017
34
Treatment of Peripheral T-Cell Lymphoma in Community Settings. ( 28622960 )
2017
35
Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. ( 29333403 )
2017
36
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. ( 28664499 )
2017
37
Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. ( 28900149 )
2017
38
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. ( 28771889 )
2017
39
Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. ( 28712310 )
2017
40
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. ( 27858107 )
2017
41
Peripheral T-cell lymphoma, not otherwise specified accompanied by central nervous system involvement with features of lymphomatosis cerebri. ( 28781271 )
2017
42
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. ( 27885817 )
2017
43
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. ( 28597542 )
2017
44
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. ( 28053548 )
2017
45
Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. ( 28883272 )
2017
46
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
47
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
48
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. ( 27983760 )
2016
49
Peripheral T-cell lymphoma mimicking Schnitzler syndrome. ( 27321901 )
2016
50
Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. ( 27152635 )
2016

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 BCL6 ETV6 GZMB
2 10.98 BCL6 MS4A1
3
Show member pathways
10.84 GZMB NME1
4 9.97 ETV6 GZMB

GO Terms for Peripheral T-Cell Lymphoma

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hippocampus development GO:0021766 8.96 ALK NME1
2 regulation of apoptotic process GO:0042981 8.8 ALK BCL6 NME1

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 8.8 BCL6 ETV6 NME1

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....